AI/ML Innovations Inc. Appoints Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has appointed Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships. Dr. Rabinowitz brings over two decades of experience in clinical cardiology and healthcare strategy, currently serving as Clinical Associate Professor in Cardiology at UBC and previously as Director of the Coronary Care Unit at St. Paul's Hospital.
Dr. Rabinowitz's expertise spans entrepreneurial ventures in advanced diagnostics and personalized medicine, with a focus on integrating artificial intelligence in cardiology. He holds a medical degree from the University of Cape Town, with specializations from the University of Toronto and UBC.
The company also announced a stock option grant of 400,000 shares at $0.105 per share to an officer, vesting quarterly over two years. AIML focuses on AI and machine learning in digital health through various subsidiaries and partnerships, including Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal, and AI Rx.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) ha nominato Dr. Alan Rabinowitz come Chief Medical Officer e Direttore delle Partnership Mediche. Il Dr. Rabinowitz porta con sé oltre due decenni di esperienza in cardiologia clinica e strategia sanitaria, attualmente ricoprendo il ruolo di Professore Associato Clinico in Cardiologia presso l'UBC e in precedenza come Direttore dell'Unità di Cura Coronaria presso l'Ospedale St. Paul's.
La competenza del Dr. Rabinowitz si estende a iniziative imprenditoriali in diagnosi avanzate e medicina personalizzata, con un focus sull'integrazione dell'intelligenza artificiale in cardiologia. Ha conseguito una laurea in medicina presso l'Università di Cape Town, con specializzazioni presso l'Università di Toronto e l'UBC.
La società ha anche annunciato una concessione di opzioni azionarie di 400.000 azioni a $0,105 per azione a un dirigente, che matureranno trimestralmente nel corso di due anni. AIML si concentra su AI e machine learning nella salute digitale attraverso varie filiali e partnership, tra cui Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal e AI Rx.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) ha nombrado al Dr. Alan Rabinowitz como Director Médico y Director de Alianzas Médicas. El Dr. Rabinowitz aporta más de dos décadas de experiencia en cardiología clínica y estrategia de atención médica, sirviendo actualmente como Profesor Asociado Clínico en Cardiología en UBC y anteriormente como Director de la Unidad de Cuidados Coronarios en el Hospital St. Paul's.
La experiencia del Dr. Rabinowitz abarca iniciativas empresariales en diagnósticos avanzados y medicina personalizada, con un enfoque en la integración de inteligencia artificial en cardiología. Tiene un título de medicina de la Universidad de Ciudad del Cabo, con especializaciones de la Universidad de Toronto y UBC.
La empresa también anunció una concesión de opciones sobre acciones de 400,000 acciones a $0.105 por acción a un funcionario, que se otorgarán trimestralmente durante dos años. AIML se centra en la IA y el aprendizaje automático en la salud digital a través de varias subsidiarias y asociaciones, incluyendo Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal y AI Rx.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)는 Dr. Alan Rabinowitz를 최고 의료 책임자 및 의료 파트너십 이사로 임명했습니다. Rabinowitz 박사는 임상 심장병학 및 의료 전략 분야에서 20년 이상의 경력을 가지고 있으며, 현재 UBC에서 심장병학의 임상 부교수로 재직 중이며, 이전에는 St. Paul's Hospital의 관상동맥 집중 치료 부서 이사로 근무했습니다.
Rabinowitz 박사는 고급 진단 및 개인 맞춤형 의학 분야의 기업가적 경력을 보유하고 있으며, 심장병학에 인공지능을 통합하는 데 중점을 두고 있습니다. 그는 케이프타운 대학교에서 의학 학위를 받았으며, 토론토 대학교와 UBC에서 전문화 과정을 이수했습니다.
회사는 또한 400,000주를 주당 $0.105에 임원에게 부여하는 주식 옵션을 발표했으며, 이는 2년에 걸쳐 분기별로 행사됩니다. AIML은 Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal 및 AI Rx를 포함한 다양한 자회사와 파트너십을 통해 디지털 건강 분야에서 AI 및 기계 학습에 집중하고 있습니다.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) a nommé Dr. Alan Rabinowitz au poste de directeur médical et directeur des partenariats médicaux. Le Dr. Rabinowitz apporte plus de vingt ans d'expérience en cardiologie clinique et en stratégie de santé, occupant actuellement le poste de professeur associé clinique en cardiologie à l'UBC et ayant auparavant été directeur de l'unité de soins coronariens à l'hôpital St. Paul's.
L'expertise du Dr. Rabinowitz couvre des initiatives entrepreneuriales dans les diagnostics avancés et la médecine personnalisée, avec un accent sur l'intégration de l'intelligence artificielle en cardiologie. Il est titulaire d'un diplôme de médecine de l'Université de Cape Town, avec des spécialisations de l'Université de Toronto et de l'UBC.
La société a également annoncé une attribution d'options sur actions de 400 000 actions à 0,105 $ par action à un dirigeant, avec un plan d'acquisition trimestriel sur deux ans. AIML se concentre sur l'IA et l'apprentissage automatique dans la santé numérique par le biais de diverses filiales et partenariats, y compris Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal et AI Rx.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) hat Dr. Alan Rabinowitz zum Chief Medical Officer und Direktor für medizinische Partnerschaften ernannt. Dr. Rabinowitz bringt über zwei Jahrzehnte Erfahrung in klinischer Kardiologie und Gesundheitsstrategie mit und fungiert derzeit als klinischer außerordentlicher Professor für Kardiologie an der UBC sowie zuvor als Direktor der Koronare Intensivstation am St. Paul's Hospital.
Die Expertise von Dr. Rabinowitz erstreckt sich über unternehmerische Initiativen in der fortgeschrittenen Diagnostik und personalisierten Medizin, mit einem Fokus auf die Integration von künstlicher Intelligenz in die Kardiologie. Er hat einen medizinischen Abschluss von der University of Cape Town, mit Spezialisierungen von der University of Toronto und UBC.
Das Unternehmen gab außerdem die Gewährung von 400.000 Aktienoptionen zu einem Preis von 0,105 USD pro Aktie an einen Mitarbeiter bekannt, die über einen Zeitraum von zwei Jahren vierteljährlich fällig werden. AIML konzentriert sich auf KI und maschinelles Lernen in der digitalen Gesundheit durch verschiedene Tochtergesellschaften und Partnerschaften, einschließlich Quantum Sciences, NeuralCloud Solutions, Health Gauge, Tech2Heal und AI Rx.
- Appointment of experienced cardiology expert as CMO strengthens medical leadership
- Strategic addition to enhance AI-driven healthcare solutions development
- Dilutive effect of 400,000 new stock options grant at $0.105 per share
Cardiologist and Visionary Joins Executive Leadership Team
Reinforces Commitment to Cutting-Edge Digital Healthcare Solutions
VANCOUVER, BC / ACCESS Newswire / January 27, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Alan Rabinowitz, a globally recognized leader in cardiology and healthcare innovation, as Chief Medical Officer (CMO) and Director of Medical Partnerships. Dr. Rabinowitz's exceptional expertise will be instrumental in guiding AIML's next generation of AI-driven healthcare solutions.
Dr. Rabinowitz has a dynamic career spanning over two decades in clinical cardiology and healthcare strategy. He served as Director of the Coronary Care Unit at St. Paul's Hospital and is currently a Clinical Associate Professor in the Division of Cardiology at the University of British Columbia ("UBC"). A sought-after advisor to healthcare organizations worldwide, Dr. Rabinowitz is known for pioneering approaches to disruptive innovation, healthcare technology integration, and data-driven medicine.
In addition to his academic and clinical contributions, Dr. Rabinowitz has led numerous entrepreneurial ventures, with a particular focus on transforming patient care through advanced diagnostics and personalized medicine. He has been a key contributor to projects that integrate artificial intelligence with cardiology, enabling faster, more accurate diagnostics and proactive patient management. Dr. Rabinowitz holds a medical degree from the University of Cape Town, with further specialization in internal medicine and cardiology at the University of Toronto, followed by interventional cardiology training at UBC.
Paul Duffy, CEO of AIML, comments "Dr. Rabinowitz is a visionary leader in the field of cardiology and digital health innovation. His extensive clinical and entrepreneurial experience will be invaluable as we expand our portfolio of AI-driven healthcare solutions. His leadership strengthens our ability to deliver transformative technologies that empower patients and improve healthcare outcomes globally."
Mark Orsmond, Executive Chairman of AIML, added "The addition of Dr. Rabinowitz to our leadership team underscores AIML's unwavering commitment to advancing healthcare innovation. His contributions will play a pivotal role in shaping our strategic direction and accelerating our impact in the digital health sector."
Stock Option Grant
The Company further announces the grant of stock options to an officer of the Company to purchase up to 400,000 common shares of the Company ("Shares") at an exercise price of
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.
About AI/ML Innovations Inc. https://aiml-innovations.com/
AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its acquisition of Quantum Sciences Ltd. (
On behalf of the Board of Directors:
Mark Orsmond, Executive Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the exercise price and vesting schedule for AIMLF's new stock options grant?
What are Dr. Alan Rabinowitz's qualifications and experience joining AIMLF?
What companies does AIMLF currently own or have partnerships with?
What is AIMLF's current business focus and strategy?
